Twenty-five years ago, Carle Cancer Center was among the first to be designated by the National Cancer Institute as a Community Clinical Oncology Program (CCOP). The Institute has again recognized the Center with a $4.8 million grant to continue research efforts and community education. The five-year award is the sixth for the Center, the first received in 1983.
“The CCOP award is significant to our program, as it funds about 90 percent of our trials,” said Kendrith Rowland, MD, principle investigator of oncology research at Carle Clinic. “This is a competitive award, and year after year, we demonstrate our commitment to quality and results. The funding really speaks to our ability to consistently provide leading-edge care and confirms our place on the front lines of cancer treatment.”
Dr. Rowland went on to add that the program’s success is due, in large part, to individuals who support cancer research by choosing clinical trials as a treatment option.
Carle Cancer Center is one of 49 CCOP-designated centers in the U. S. and one of 17 to receive funding this year.
Carle Cancer Center recently relocated to a new $50 million, 100,000 square-foot facility designed for patient comfort and equipped with the latest technology, including TomoTherapy. The Center offers more than 100 clinical trials for cancer prevention and treatment.